Physician

Mussa Banisadre, MD

According to 2025 Medicare claims, Mussa Banisadre, MD (NPI: 1043264690) practices hematology in the Modesto, CA market, with the plurality of this provider's patient population coming from Stanislaus, CA. This provider's primary affiliated billing organization is STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (NPI: 1922175074; TIN: 20-3850829) and primary practice location at 95350-5581.

Banisadre's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 293 traditional Medicare patients, billed 66,362 HCPCS/CPT codes, and received $1,124,159 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,381 prescription claims across 279 beneficiaries totaling $2,295,486 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 40 claims. Open Payments data shows 94 records totaling $2,659. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,444,559 and ending at $2,295,486. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	516	53,963	$1,047,609
2016	512	69,083	$1,067,023
2017	543	60,545	$1,025,778
2018	505	64,745	$937,952
2019	437	52,308	$511,486
2020	268	50,594	$534,392
2021	256	26,243	$315,069
2022	262	23,405	$290,314
2023	286	74,037	$650,965
2024	293	66,362	$1,124,159

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	267	1,632	$1,444,559
2016	258	1,541	$1,293,965
2017	299	1,594	$2,097,280
2018	318	1,656	$1,720,217
2019	288	1,579	$2,455,864
2020	235	1,252	$1,528,915
2021	273	1,615	$2,162,040
2022	266	1,392	$2,034,077
2023	308	1,519	$1,738,578
2024	279	1,381	$2,295,486

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	71	$43,595
2016	N/R	100	$32,293
2017	28	165	$36,975
2018	11	105	$17,656
2019	N/R	45	$5,569
2020	N/R	40	$3,559
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	30	214	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	252	571	$81
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	47	65	$55
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	32	242	$21
96375	Injection of additional new drug or substance into vein	27	255	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,204	$657,075
Brukinsa	Zanubrutinib	20	600	$271,337
Lenalidomide	Lenalidomide	25	718	$264,249
Kisqali	Ribociclib Succinate	13	364	$220,024
Tagrisso	Osimertinib Mesylate	11	330	$173,719

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$2,659	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mussa Banisadre, MD?

Tedicare shows public-source Medicare data for Mussa Banisadre, MD (NPI 1043264690), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mussa Banisadre, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mussa Banisadre, MD?

Mussa Banisadre, MD is linked to STOCKTON HEMATOLOGY ONCOLOGY MEDICAL GROUP, INC (billing NPI 1922175074) in the available physician profile data.

Does Mussa Banisadre, MD have Open Payments data?

Mussa Banisadre, MD has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.